Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Beijing Biotech
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07627711CT.gov Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | — | Recruiting | — | — | — |
NCT07523529CT.gov Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07404332CT.gov 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | — | Recruiting | — | — | — |
NCT07094113CT.gov AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07046923CT.gov A Study of LY4175408 in Participants With Advanced Cancer | — | Recruiting | — | — | — |
NCT06395090CT.gov A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | — | Withdrawn | — | — | — |
NCT06460961CT.gov A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) | — | Active Not Recruiting | — | — | — |
NCT06383507CT.gov A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06119581CT.gov A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06072612CT.gov Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | — | Recruiting | — | — | — |
Show 17 more trialsShow fewer
NCT05614739CT.gov FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | — | Recruiting | — | — | — |
NCT05468190CT.gov A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | — | Unknown | — | — | — |
NCT05518253CT.gov A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05420545CT.gov A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | — | Unknown | — | — | — |
NCT05420519CT.gov Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | — | Unknown | — | — | — |
NCT05415475CT.gov Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | — | Unknown | — | — | — |
NCT04521621CT.gov A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | — | Terminated | — | — | — |
NCT04294576CT.gov Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors | — | Unknown | — | — | — |
NCT03383094CT.gov Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT03257722CT.gov Pembrolizumab + Idelalisib for Lung Cancer Study | — | Terminated | — | — | — |
NCT02775292CT.gov Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | — | Completed | — | — | — |
NCT02414269CT.gov Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | — | Active Not Recruiting | — | — | — |
NCT02376699CT.gov Safety Study of SEA-CD40 in Cancer Patients | — | Terminated | — | — | — |
NCT02054104CT.gov Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | — | Terminated | — | — | — |
NCT00246103CT.gov Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies | — | Completed | — | — | — |
NCT00048893CT.gov Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00001832CT.gov Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Beijing Biotech | P3 | B · 62 |
| Oxaliplatin | Ruijin Hospital | P4 | BBB |
| Fluorouracilum | Ruijin Hospital | P4 | BBB |
| Irinotecan | Eli Lilly and Company | P4 | BBB |
| Dexasone | Janssen Research & Development, LLC | P2 | BBB |
| Atezolizumab | UNC Lineberger Comprehensive Cancer Center | P2/3 | BB |
| Ipilimumab | 7 Hills Pharma, LLC | P3 | BB |
| Trastuzumab | City of Hope Medical Center | P3 | BB |
| (+)-Vincristine | Eli Lilly and Company | P4 | BB |
+41 more in the Metastatic Neoplasm cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Metastatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-metastatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →